Utilization and expense of adjuvant cancer therapies following radical prostatectomy

Stephen Williams, Xiangmei Gu, Stuart R. Lipsitz, Paul L. Nguyen, Toni K. Choueiri, Jim C. Hu

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

BACKGROUND: We sought to identify the costs of adjuvant therapies following radical prostatectomy (RP) and factors associated with their receipt. METHODS: We used SEER-Medicare data from 2004-2006 to identify 4247 men who underwent RP, of whom 600 subsequently received adjuvant therapies. We used Cox regression to identify factors associated with receipt of adjuvant therapies. Health care expenditures within 12 months of diagnosis were compared for RP alone versus RP with adjuvant therapies. RESULTS: Biopsy Gleason score, prostate-specific antigen, risk group, and SEER region were significantly associated with receipt of adjuvant treatments (all P

Original languageEnglish (US)
Pages (from-to)4846-4854
Number of pages9
JournalCancer
Volume117
Issue number21
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

Prostatectomy
Neoplasms
Therapeutics
Neoplasm Grading
Prostate-Specific Antigen
Health Expenditures
Medicare
Delivery of Health Care
Biopsy
Costs and Cost Analysis

Keywords

  • adjuvant therapy
  • expenditures
  • outcomes
  • prostatectomy
  • utilization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Williams, S., Gu, X., Lipsitz, S. R., Nguyen, P. L., Choueiri, T. K., & Hu, J. C. (2011). Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer, 117(21), 4846-4854. https://doi.org/10.1002/cncr.26012

Utilization and expense of adjuvant cancer therapies following radical prostatectomy. / Williams, Stephen; Gu, Xiangmei; Lipsitz, Stuart R.; Nguyen, Paul L.; Choueiri, Toni K.; Hu, Jim C.

In: Cancer, Vol. 117, No. 21, 01.11.2011, p. 4846-4854.

Research output: Contribution to journalArticle

Williams, S, Gu, X, Lipsitz, SR, Nguyen, PL, Choueiri, TK & Hu, JC 2011, 'Utilization and expense of adjuvant cancer therapies following radical prostatectomy', Cancer, vol. 117, no. 21, pp. 4846-4854. https://doi.org/10.1002/cncr.26012
Williams, Stephen ; Gu, Xiangmei ; Lipsitz, Stuart R. ; Nguyen, Paul L. ; Choueiri, Toni K. ; Hu, Jim C. / Utilization and expense of adjuvant cancer therapies following radical prostatectomy. In: Cancer. 2011 ; Vol. 117, No. 21. pp. 4846-4854.
@article{868d327740424ec8b3117c8c293383dc,
title = "Utilization and expense of adjuvant cancer therapies following radical prostatectomy",
abstract = "BACKGROUND: We sought to identify the costs of adjuvant therapies following radical prostatectomy (RP) and factors associated with their receipt. METHODS: We used SEER-Medicare data from 2004-2006 to identify 4247 men who underwent RP, of whom 600 subsequently received adjuvant therapies. We used Cox regression to identify factors associated with receipt of adjuvant therapies. Health care expenditures within 12 months of diagnosis were compared for RP alone versus RP with adjuvant therapies. RESULTS: Biopsy Gleason score, prostate-specific antigen, risk group, and SEER region were significantly associated with receipt of adjuvant treatments (all P",
keywords = "adjuvant therapy, expenditures, outcomes, prostatectomy, utilization",
author = "Stephen Williams and Xiangmei Gu and Lipsitz, {Stuart R.} and Nguyen, {Paul L.} and Choueiri, {Toni K.} and Hu, {Jim C.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1002/cncr.26012",
language = "English (US)",
volume = "117",
pages = "4846--4854",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "21",

}

TY - JOUR

T1 - Utilization and expense of adjuvant cancer therapies following radical prostatectomy

AU - Williams, Stephen

AU - Gu, Xiangmei

AU - Lipsitz, Stuart R.

AU - Nguyen, Paul L.

AU - Choueiri, Toni K.

AU - Hu, Jim C.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - BACKGROUND: We sought to identify the costs of adjuvant therapies following radical prostatectomy (RP) and factors associated with their receipt. METHODS: We used SEER-Medicare data from 2004-2006 to identify 4247 men who underwent RP, of whom 600 subsequently received adjuvant therapies. We used Cox regression to identify factors associated with receipt of adjuvant therapies. Health care expenditures within 12 months of diagnosis were compared for RP alone versus RP with adjuvant therapies. RESULTS: Biopsy Gleason score, prostate-specific antigen, risk group, and SEER region were significantly associated with receipt of adjuvant treatments (all P

AB - BACKGROUND: We sought to identify the costs of adjuvant therapies following radical prostatectomy (RP) and factors associated with their receipt. METHODS: We used SEER-Medicare data from 2004-2006 to identify 4247 men who underwent RP, of whom 600 subsequently received adjuvant therapies. We used Cox regression to identify factors associated with receipt of adjuvant therapies. Health care expenditures within 12 months of diagnosis were compared for RP alone versus RP with adjuvant therapies. RESULTS: Biopsy Gleason score, prostate-specific antigen, risk group, and SEER region were significantly associated with receipt of adjuvant treatments (all P

KW - adjuvant therapy

KW - expenditures

KW - outcomes

KW - prostatectomy

KW - utilization

UR - http://www.scopus.com/inward/record.url?scp=80054819859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054819859&partnerID=8YFLogxK

U2 - 10.1002/cncr.26012

DO - 10.1002/cncr.26012

M3 - Article

C2 - 21365630

AN - SCOPUS:80054819859

VL - 117

SP - 4846

EP - 4854

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 21

ER -